"question is (licensing aside as a seperate profit

"question is (licensing aside as a seperate profit center), do you accept a LymPro JV Agreement now and encumber the asset, or do you hold off until spin-off"

That's the multi-million dollar question which they didn't finalize last month it looks like. They are going to need money one way or another for all these acquisitions and the phases. And then there is the question of when do you uplist. Seems like the uplist was always viewed happening prior to spinout.

Remember Gerald almost said "We received" on the call and changed it to we are various stages. From my previous post after the Dec. 2 update call. I think all options are considered:

Quote:

---

Previously when the company spoke about Lympro or the Diagnostic division it was we "may" spinout or "considering". Now it looks a little more certain with "now preparing" and just Lympro. Diagnostic division spinout/divestiture wasn't mentioned. This is the first time I remember "divestiture" being mentioned which is selling it as opposed to spinning out. Seems like they have a lot of options they are considering. Will be interesting which path they take - spinoff or divestiture. Could explain how they will be able to fund all the other initiatives.

12:20 - "We're as part of our incubation model we are now preparing to monetize this asset either through spinoff or divestiture. We ..., we're at various stages of discussions with various groups with respect to these monetizing this asset and we expect to update the market in the near future regarding our plans with this asset. We see this as a huge opportunity so we have a lot of options in terms of how we are going to go about this product."

investorshangout.com/post/view?id=2381286#ixzz3NsCeSLy0

---